// App-Quantinova.ai

EP1157 : EFFECTIVENESS AND SAFETY OF ROMIPLOSTIM IN PATIENTS WITH NEWLY DIAGNOSED, PERSISTENT AND CHRONIC PRIMARY IMMUNE THROMBOCYTOPENIA IN GERMAN ROUTINE CLINICAL PRACTICE: THE OBSERVATIONAL PLATEAU STUDY

Researchers

Presenter

  • Marcel Reiser

Principal Investigators

  • Klaus M Josten

  • Hermann Dietzfelbinger

  • Anouchka Seesaghur

  • Markus Schill

  • Jane Hippenmeyer

  • Manfred Welslau

Medical Centers

  • Praxis Fur Hamatologie Und Onkologie, Wiesbaden, Germany

  • Amgen,Rotkreuz,Switzerland

  • Hämatologisch-onkologische Schwerpunktpraxis,Bochum,Germany

  • Onkologie Aschaffenburg, Aschaffenburg, Germany

  • Amgen GmbH, Munich, Germany

  • Praxis Internistische Onkologie und Hämatologie (PIOH),Köln,Germany

  • Amgen Ltd,London,United Kingdom

Locations

  • Germany

  • Switzerland

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Immune thrombocytopenia

Biomarkers

  • N/A

Drug/Treatment

  • Romiplostim

Outcome

  • N/A

Study Design

  • Observational

  • Single Arm

  • Prospective

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved